Gufic Biosciences scales record high after posting robust Q2 results

Gufic Biosciences jumped 8.5% to Rs 106 at 11:23 IST on BSE after net profit surged 113.54% to Rs 5.67 crore on 13.29% rise in total income to Rs 75.69 crore in Q2 September 2017 over Q2 September 2016.

The result was announced before market hours today, 15 December 2017.

Meanwhile, the S&P BSE Sensex was up 266.24 points, or 0.8% at 33,512.94. The S&P BSE Small-Cap index was up 223.78 points, or 1.25% at 18,147.23, outperforming the Sensex.

More than usual volumes were witnessed on the counter. On the BSE, 1.65 lakh shares were traded on the counter so far as against the average daily volume of 1.05 lakh shares in the past one quarter. The stock had hit a high of Rs 108.55 in intraday trade, which is also a record high for the stock. The stock had hit a low of Rs 99.50 so far during the day. The stock had hit a 52-week low of Rs 49.10 on 22 December 2016.

The stock gained 13.14% over the past one month till 14 December 2017, outperforming the Sensex's 0.93% rise. The scrip had also outperformed the market in past one quarter, jumping 40.78% as against Sensex's 3.12% rise. The scrip had also outperformed the market in past one year, surging 88.07% as against Sensex's 24.97% rise.

The small-cap company has equity capital of Rs 7.74 crore. Face value per share is Rs 1.

Gufic Biosciences is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.

Powered by Capital Market - Live News